加载中
NASDAQHealthcareDrug Manufacturers - Specialty & Generic
最新数据
US$1.375
−US$0.155 · -10.13%
Evotec SE operates globally as a dedicated partner, specializing in the discovery and advancement of new pharmaceutical products for the biotechnology and pharmaceutical sectors. Its comprehensive research and development initiatives encompass a broad spectrum of medical areas, such as metabolic disorders (including diabetes and its complications), fibrosis, infectious conditions, central nervous system (CNS) diseases, oncology, pain management, inflammatory ailments, immunological dysfunctions, rare diseases, respiratory conditions, and women's health. The company maintains strategic alliances and collaborations with numerous prominent organizations, including Bayer AG, Lilly, Chinook Therapeutics, Novo Nordisk A/S, Galapagos, Pfizer Inc., CONBA Pharmaceutical Co., Ltd., Bristol Myers Squibb Company, Zhejiang JingXin Pharmaceutical Co., Ltd, Kazia Therapeutics, Apeiron Biologics, and Takeda Pharmaceuticals. Established in 1993, the company was formerly known as Evotec AG, changing its name to Evotec SE in April 2019. Its corporate headquarters are located in Hamburg, Germany.
常规交易时段
US$1.375
−US$0.155 · -10.13%
盘中时间采用ET。市场数据可能有所延迟。
Evotec SE operates globally as a dedicated partner, specializing in the discovery and advancement of new pharmaceutical products for the biotechnology and pharmaceutical sectors. Its comprehensive research and development initiatives encompass a broad spectrum of medical areas, such as metabolic disorders (including diabetes and its complications), fibrosis, infectious conditions, central nervous system (CNS) diseases, oncology, pain management, inflammatory ailments, immunological dysfunctions, rare diseases, respiratory conditions, and women's health. The company maintains strategic alliances and collaborations with numerous prominent organizations, including Bayer AG, Lilly, Chinook Therapeutics, Novo Nordisk A/S, Galapagos, Pfizer Inc., CONBA Pharmaceutical Co., Ltd., Bristol Myers Squibb Company, Zhejiang JingXin Pharmaceutical Co., Ltd, Kazia Therapeutics, Apeiron Biologics, and Takeda Pharmaceuticals. Established in 1993, the company was formerly known as Evotec AG, changing its name to Evotec SE in April 2019. Its corporate headquarters are located in Hamburg, Germany.
日内区间
当前US$1.375
52周区间
当前US$1.375
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
卖出
估值
47
合理估值
情绪
45
多空交织
风险
60
风险偏高
动量
30
动能减弱
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Evotec SE operates globally as a dedicated partner, specializing in the discovery and advancement of new pharmaceutical products for the biotechnology and pharmaceutical sectors. Its comprehensive research and development initiatives encompass a broad spectrum of medical areas, such as metabolic disorders (including diabetes and its complications), fibrosis, infectious conditions, central nervous system (CNS) diseases, oncology, pain management, inflammatory ailments, immunological dysfunctions, rare diseases, respiratory conditions, and women's health. The company maintains strategic alliances and collaborations with numerous prominent organizations, including Bayer AG, Lilly, Chinook Therapeutics, Novo Nordisk A/S, Galapagos, Pfizer Inc., CONBA Pharmaceutical Co., Ltd., Bristol Myers Squibb Company, Zhejiang JingXin Pharmaceutical Co., Ltd, Kazia Therapeutics, Apeiron Biologics, and Takeda Pharmaceuticals. Established in 1993, the company was formerly known as Evotec AG, changing its name to Evotec SE in April 2019. Its corporate headquarters are located in Hamburg, Germany.
日内区间
当前US$1.375
52周区间
当前US$1.375
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（EUR） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 7.57亿 EUR | 7.97亿 EUR | 7.81亿 EUR | 7.51亿 EUR | 6.18亿 EUR |
| 销货成本 | 6.95亿 EUR | 6.82亿 EUR | 6.06亿 EUR | 5.77亿 EUR | 4.66亿 EUR |
| 毛利 | 6266.23万 EUR | 1.15亿 EUR | 1.75亿 EUR | 1.74亿 EUR | 1.52亿 EUR |
| 研究与开发 | 7432.89万 EUR | 5085.7万 EUR | 6852.9万 EUR | 7664.2万 EUR | 6569.8万 EUR |
| 销售、一般及管理费用 | 1.24亿 EUR | 1.88亿 EUR | 1.7亿 EUR | 1.56亿 EUR | 1.05亿 EUR |
| 营业费用 | 1.98亿 EUR | 2.57亿 EUR | 2.23亿 EUR | 1.53亿 EUR | 1.11亿 EUR |
| 利息收入 | 424.94万 EUR | 243.5万 EUR | 926.3万 EUR | 833.6万 EUR | 227.2万 EUR |
| 利息支出 | 1387.2万 EUR | 1169.9万 EUR | 1173.9万 EUR | 1315万 EUR | 925.4万 EUR |
| 折旧和摊销 | 9555万 EUR | 1.02亿 EUR | 9297.9万 EUR | 8319.6万 EUR | 7039.9万 EUR |
| 营业利润 | −1.35亿 EUR | −1.43亿 EUR | −4750.7万 EUR | 2085万 EUR | 4099.6万 EUR |
| 净利润 | −9943.15万 EUR | −1.96亿 EUR | −8391.3万 EUR | −1.76亿 EUR | 2.16亿 EUR |
公司数据更新于 2026年10月12日。
报告持有此股票敞口的交易所交易基金。
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
